On the contrary, sirolimus, an agent belonging to the mTOR inhibitors, such as tacrolimus, is now studied for the treatment of lung, pancreatic, and gastrointestinal NET [22]. This evidence concerns the gene MTOR and digestive system neuroendocrine tumor, grade 1/2.